1 Dolecek TA,Propp JM,Stroup NE,et al.CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2005-2009[J].Neuro Oncol,2012,14(5):1-49. 2 Louis DN,Perry A,Reifenberger G,et al.The 2016 world health organization classification of tumors of the central nervous system:a summary[J].Acta Neuropathol,2016,131(6):803-820. 3 董天华,沈欣,梁亚男,等.脑胶质瘤中CDK4和β-Catenin表达及临床意义的研究[J].实用肿瘤学杂志,2015,29(5):404-408. 4 Bush NA,Chang SM,Berger MS.Current and future strategies for treatment of glioma[J].Neurosurg Rev,2017,40(1):1-14. 5 Elinav E,Nowarski R,Thaiss CA,et al.Inflammation-induced cancer:crosstalk between tumors,immune cells and microorganisms[J].Nat Rev Cancer,2013,13(11):759-771. 6 Grivennikov SI,Greten FR,Karin M.Immunity,inflammation,and cancer[J].Cell,2010,140(6):883-899. 7 Balkwill F,Mantovani A.Inflammation and cancer:back to Virchow?[J].Lancet,2001,357(9255):539-545. 8 Ostrom QT,Gittleman H,Stetson L,et al.Epidemiology of gliomas[J].Cancer Treat Res,2015,163:1-14. 9 Wiencke JK,Koestler DC,Salas LA,et al.Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio(NLR)in glioma survival[J].Clin Epigenetics,2017,9:10. 10 Degenhardt K,Mathew R,Beaudoin B,et al.Autophagy promotes tumor cell survival and restricts necrosis,inflammation,and tumorigenesis[J].Cancer Cell,2006,10(1):51-64. 11 Dougan M,Dranoff G.Immune therapy for cancer[J].Annu Rev Immunol,2009,27:83-117. 12 Guthrie GJ,Charles KA,Roxburgh CS,et al.The systemic inflammation-based neutrophil-lymphocyte ratio:experience in patients with cancer[J].Crit Rev Oncol Hematol,2013,88(1):218-230. 13 McNamara MG,Lwin Z,Jiang H,et al.Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era,incorporating neutrophil/lymphocyte ratio and time to first progression[J].J Neurooncol,2014,117(1):147-152. 14 Bambury RM,Teo MY,Power DG,et al.The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme[J].J Neuro Oncol,2013,114(1):149-154. 15 Xu L,Yu S,Zhuang L,et al.Systemic inflammation response index(SIRI)predicts prognosis in hepatocellular carcinoma patients[J].Oncotarget,2017,8(21):34954-34960. 16 Reuss DE,Mamatjan Y,Schrimpf D,et al.IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival:a grading problem for WHO[J].Acta Neuropathol,2015,129(6):867-873. |